Clinical Trial Update: A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury. [Phase 2]

View source ↗

Summary

A Phase 2 trial assessed the safety and efficacy of pirfenidone in patients with Grade 2 or Grade 3 radiation-induced lung injury and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Radiation-induced Lung Injury

Drugs mentioned

• PIRFENIDONE (pirfenidone)

Snippet

Sponsor: Beijing Continent Pharmaceutical Co, Ltd. | Conditions: Radiation-induced Lung Injury | Phase 2 | Status: COMPLETED